Programmedcell death ligand 1 (PD-L1) signaling regulates macrophage proliferation and activation

Cancer Immunology Research

Volumn 6, Issue 10, 2018, Pages 1260-1273

  Hartley, Genevieve P ^a   Chow, Lyndah ^a   Ammons, Dylan T ^a   Wheat, William H ^a   Dow, Steven W ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD274 PROTEIN, MOUSE; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECT; EXPERIMENTAL MELANOMA; HUMAN; IMMUNOLOGY; MACROPHAGE; MACROPHAGE ACTIVATION; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; B7-H1 ANTIGEN; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; MACROPHAGE ACTIVATION; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; MICE, TRANSGENIC; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION;

EID: 85054397060     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-17-0537     Document Type: Article

References (48)

1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
2. Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol 2014;4:385.
3. First-line atezolizumab effective in bladder cancer. Cancer Discov 2016;6: OF7.
4. Massard C, GordonMS, Sharma S, Rafii S,Wainberg ZA, Luke J, et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016;34:3119-25.
5. Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 2015;3:1148-57.
6. Wang Y, Wang H, Zhao Q, Xia Y, Hu X, Guo J. PD-L1 induces epithelial-tomesenchymal transition via activating SREBP-1c in renal cell carcinoma. Med Oncol 2015;32:655.
7. Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, et al. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells. Mol Cancer 2015;14:149.
8. Yang Y, Wu KE, Zhao E, Li W, Shi L, Xie G, et al. B7-H1 enhances proliferation ability of gastric cancer stem-like cells as a receptor. Oncol Lett 2015;9:1833-1838.
9. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008;111:3635-43.
10. Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 2015;162:1229-41.
11. Dong L, Lv H, Li W, Song Z, Li L, Zhou S, et al. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. Oncotarget 2016;7:33350-62.
12. BlackM, Barsoum IB, Truesdell P, Cotechini T, Macdonald-Goodfellow SK, Petroff M, et al. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. Oncotarget 2016;7:10557-67.
13. Kuipers H,Muskens F,Willart M, Hijdra D, van Assema FB, Coyle AJ, et al. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cellmediated CD4+ T cell activation. Eur J Immunol 2006;36:2472-82.
14. Lee Y-J, Kyeong Eun Hyung Y-HM, Yoo J-S, Lee MJ, Lee IH, Go BS, et al. Macrophage PD-L1 strikes back: PD-1/PD-L1 interaction drives macrophages towards regulatory subsets. Adv Biosci Biotech 2013;4:19-29.
15. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014;515:563-7.
16. Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra37.
17. Schultheis AM, Scheel AH, Ozretic L, George J, Thomas RK, Hagemann T, et al. PD-L1 expression in small cell neuroendocrine carcinomas. Eur J Cancer 2015;51:421-6.
18. Hartley G, Regan D, Guth A, Dow S. Regulation of PD-L1 expression on murine tumor-associated monocytes and macrophages by locally produced TNF-alpha. Cancer Immunol Immunother 2017;66:523-535.
19. Simioni C, Cani A, Martelli AM, Zauli G, Tabellini G, McCubrey J, et al. Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation. Oncotarget 2014;5:10034-47.
20. Zullo AJ, Jurcic Smith KL, Lee S. Mammalian target of rapamycin inhibition and mycobacterial survival are uncoupled in murine macrophages. BMC Biochem 2014;15:4.
21. Sinclair C, Bommakanti G, Gardinassi L, Loebbermann J, Johnson MJ, Hakimpour P, et al. mTOR regulates metabolic adaptation of APCs in the lung and controls the outcome of allergic inflammation. Science 2017;357: 1014-1021.
22. Demoulin JB, Montano-Almendras CP. Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. Am J Blood Res 2012;2:44-56.
23. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007;6: 137-43.
24. Asada K, Sasaki S, Suda T, Chida K, Nakamura H. Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am J Respir Crit Care Med 2004;169:195-200.
25. Beyaert R, Heyninck K, Van Huffel S. A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol 2000;60:1143-51.
26. Parameswaran N, Patial S. Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr 2010;20:87-103.
27. Harwood SM, Yaqoob MM, Allen DA. Caspase and calpain function in cell death: bridging the gap between apoptosis and necrosis. Ann Clin Biochem 2005;42:415-31.
28. Giorgi C, Bonora M, Sorrentino G, Missiroli S, Poletti F, Suski JM, et al. p53 at the endoplasmic reticulum regulates apoptosis in a Ca2+-dependent manner. Proc Natl Acad Sci USA 2015;112:1779-84.
29. Suzuki T, Hashimoto S, Toyoda N, Nagai S, Yamazaki N, Dong HY, et al. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 2000;96:2584-91.
30. Zhao A, Yang Z, Sun R, Grinchuk V, Netzel-Arnett S, Anglin IE, et al. SerpinB2 is critical to Th2 immunity against enteric nematode infection. J Immunol 2013;190:5779-87.
31. Reigstad CS, Lunden GO, Felin J, Backhed F. Regulation of serum amyloid A3 (SAA3) in mouse colonic epithelium and adipose tissue by the intestinal microbiota. PLoS One 2009;4:e5842.
32. Anthony D, McQualter JL, Bishara M, Lim EX, Yatmaz S, Seow HJ, et al. SAA drives proinflammatory heterotypic macrophage differentiation in the lung via CSF-1R-dependent signaling. FASEB J 2014;28: 3867-77.
33. van Zuylen WJ, Garceau V, Idris A, Schroder K, Irvine KM, Lattin JE, et al. Macrophage activation and differentiation signals regulate schlafen-4 gene expression: evidence for Schlafen-4 as a modulator of myelopoiesis. PLoS One 2011;6:e15723.
34. Yeramian A, Martin L, Arpa L, Bertran J, Soler C, McLeod C, et al. Macrophages require distinct arginine catabolism and transport systems for proliferation and for activation. Eur J Immunol 2006;36:1516-26.
35. Lee HY, Kim SD, Shim JW, Kim HJ, Kwon JY, Kim JM, et al. Activation of human monocytes by a formyl peptide receptor 2-derived pepducin. FEBS Lett 2010;584:4102-8.
36. Nakano T, Fukuda D, Koga J, Aikawa M. Delta-like ligand 4-notch signaling in macrophage activation. Arterioscler Thromb Vasc Biol 2016;36:2038-47.
37. Radjabova V, Mastroeni P, Skjodt K, Zaccone P, de Bono B, Goodall JC, et al. TARM1 is a novel leukocyte receptor complex-encoded ITAM receptor that costimulates proinflammatory cytokine secretion by macrophages and neutrophils. J Immunol 2015;195:3149-59.
38. Oliveira LJ, McClellan S, Hansen PJ. Differentiation of the endometrial macrophage during pregnancy in the cow. PLoS One 2010;5:e13213.
39. Feingold KR, Shigenaga JK, Cross AS, Moser A, Grunfeld C. Angiopoietin like protein 4 expression is decreased in activated macrophages. Biochem Biophys Res Commun 2012;421:612-5.
40. De Paoli F, Copin C, Vanhoutte J, Derudas B, Vinod M, Zawadzki C, et al. Transducin-like enhancer of split-1 is expressed and functional in human macrophages. FEBS Lett 2016;590:43-52.
41. Nguyen KD, Qiu Y, Cui X, Goh YP, Mwangi J, David T, et al. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature 2011;480:104-8.
42. Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell 2015;162:1242-56.
43. Fleetwood AJ, Lawrence T, Hamilton JA, Cook AD. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J Immunol 2007;178:5245-52.
44. Zhang L, Wang Y, Xiao F, Wang S, Xing G, Li Y, et al. CKIP-1 regulates macrophage proliferation by inhibiting TRAF6-mediated Akt activation. Cell Res 2014;24:742-61.
45. Covarrubias AJ, Aksoylar HI, Horng T. Control of macrophage metabolism and activation by mTOR and Akt signaling. Semin Immunol 2015;27: 286-96.
46. Gordon SR, Maute RL, Dulken BW, Hutter G, George BM,McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 2017;545:495-9.
47. Georgoudaki AM, Prokopec KE, Boura VF, Hellqvist E, Sohn S, Ostling J, et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep 2016;15: 2000-11.
48. Huang SC, Smith AM, Everts B, Colonna M, Pearce EL, Schilling JD, et al. Metabolic reprogramming mediated by themTORC2-IRF4 signaling axis is essential for macrophage alternative activation. Immunity 2016;45: 817-30.